Ultime notizie per Bionano Genomics (NASDAQ:BNGO) Azioni

Bionano Genomics

Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in Americas, EMEA and Asia Pacific; majority revenue being generated from Americas. They generate product revenue from sales of its OGM and Ionic Purification systems and consumables, which includes its instruments, and their VIA software.

Bionano Genomics Inc

Announced at Fal.Con Europe, CrowdStrike's inaugural premier user conference in the region, this latest expansion builds on CrowdStrike and Ignition's success in the UK and Nordics – growing their regional partner business more than 85% year-over-year – by driving customer demand for cybersecurity transformation, platform adoption and vendor consolidation.&nbsp;

News

Contracts

General

CRWD

CrowdStrike Announced An Expanded Distribution Partnership With Ignition Technology, Bringing The CrowdStrike Falcon Cybersecurity Platform To Ignition's Partner Base In Ireland.

Ceva, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEVA#NASDAQ">CEVA</a>), the leading licensor of silicon and software IP that enables Smart Edge devices to connect, sense and infer data more reliably and efficiently, today announced that its Board of Directors authorized the expansion of the company's share repurchase program with an additional 700,000 shares of common stock available for repurchase. As of September 30, 2024, Ceva had approximately 356,000 shares of common stock available for repurchase under the existing plan, bringing the aggregate to approximately 1,056,000 shares available for repurchase.

Buybacks

CEVA

Ceva's Board Approved Expansion Of Buyback Program By Additional 700K Shares

The Ultra C Tahoe now achieves the performance of standalone single-wafer cleaning tools on low-to-medium temperature sulfuric peroxide mix (SPM) processes. Tahoe's patented hybrid architecture is among the first in the industry to combine batch wafer processing and single wafer cleaning chambers into the same SPM tool. The hybrid architecture delivers enhanced cleaning performance, high throughput, and process flexibility, with up to 75% reduction in chemical consumption. ACM estimates cost savings of up to $500,000 per year from sulfuric acid alone, with additional environmental and cost benefits from reduced sulfuric acid treatment and disposal.

Tech

ACMR

ACM Research Announced A Major Performance Breakthrough For Its Flagship Ultra C Tahoe Cleaning Tool, To Meet Technical Requirements Of Advanced Nodes For Foundry, Logic And Memory Applications For Front-end Semiconductor Manufacturing

Needham analyst Mike Matson reiterates Enovis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENOV#NYSE">ENOV</a>) with a Buy and maintains $65 price target.

Price Target

Reiteration

Analyst Ratings

ENOV

Needham Reiterates Buy on Enovis, Maintains $65 Price Target

Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) has partnered with Hugging Face to advance robotics research and development using open-source <a href="https://www.benzinga.com/topic/artificial-intelligence">artificial intelligence technology</a>.
What Happened: At the Conference for Robot Learning (CoRL) in Munich, Germany, Hugging Face and Nvidia <a href="https://blogs.nvidia.com/blog/hugging-face-lerobot-open-source-robotics/">announced</a> a collaboration to expedite robotics research and development by uniting their open-source robotics communities.
This collaboration will combine Hugging Face&#8217;s LeRobot open AI platform with Nvidia&#8217;s AI, Omniverse, and Isaac robotics technology to drive advancements across various industries, including manufacturing, healthcare, and logistics.
The LeRobot platform will provide a comprehensive suite of tools for sharing data collection, model training, and simulation environments, along with designs for low-cost manipulator kits. 
Nvidia&#8217;s AI technology, simulation, and open-source robot learning modular framework, such as NVIDIA Isaac Lab, will accelerate LeRobot&#8217;s data collection, training, and verification workflow.
See Also: <a href="https://www.benzinga.com/markets/equities/24/11/41767332/trumps-potential-return-to-white-house-sends-ex-president-linked-phunware-stock-upwards-during-p?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Trump&#8217;s Potential Return To White House Sends Ex-President Linked Phunware Stock Upwards During Pre-Market Hours</a>
Why It Matters: Earlier in May, Hugging Face had partnered with Amazon.com Inc. to simplify running <a href="https://www.benzinga.com/news/24/05/38990924/amazon-and-ai-startup-hugging-face-partner-to-enhance-ai-model-efficiency">thousands of AI models</a> on Amazon&#8217;s custom computing chips. This partnership aimed to enhance AI model efficiency on Amazon Web Services (AWS) custom chip called Inferentia2.
Meanwhile, Nvidia&#8217;s new free, open-source AI model, Llama-3.1-Nemotron-70B-Instruct, has <a href="https://www.benzinga.com/news/24/10/41422278/nvidias-new-free-open-source-ai-model-reportedly-outperforms-openais-gpt-4o-anthropics-claude-3-5-so">reportedly outperformed its competitors</a> in benchmark tests. This model, built on Meta Platforms Inc.&#8216;s Llama 3.1 framework, has surpassed larger models in benchmark tests.
Back in August 2023, Hugging Face, a Nvidia-backed open-source AI startup, <a href="https://www.benzinga.com/news/23/08/34042661/nvidia-backed-open-source-ai-startup-reaches-4-5b-valuation-with-tech-titans-support">reached a $4.5 billion valuation</a> with the support of tech titans. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/11/41734887/cathie-woods-latest-shake-up-dumps-palantir-and-jack-dorseys-block-along-with-tesla-buys-amazon-?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Cathie Wood&#8217;s Latest Shake-up: Dumps Palantir And Jack Dorsey&#8217;s Block Along With Tesla, Buys Amazon And Meta</a></li>
</ul>
Image Via Shutterstock 
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Startups

AMZN

NVDA

Nvidia Partners With AI Startup Hugging Face To Supercharge Open Source Robotics

Earnings

Earnings Beats

ACM Research Q3 2024 Adj. EPS $0.63 Beats $0.37 Estimate, Sales $203.976M Beat $191.176M Estimate

CEVA Q3 2024 Adj. EPS $0.14 Beats $0.10 Estimate, Sales $27.207M Beat $26.850M Estimate

Needham analyst Laura Martin reiterates Perion Network (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PERI#NASDAQ">PERI</a>) with a Hold.

PERI

Needham Reiterates Hold on Perion Network

Virgin Galactic Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPCE#NYSE">SPCE</a>) shares closed up 3.5% on Wednesday after the company reported a net loss of $75 million for the third quarter, lower than the $105 million net loss reported in the corresponding period last year owing to lower operating expenses.
What Happened: Branson&#8217;s spaceflight company&#8217;s total operating expenses fell to $82.1 million in the third quarter from $116 million in the corresponding quarter a year ago. However, revenue also fell to $0.4 million from $1.7 million last year owing to the pause in commercial spaceflights.
Virgin Galactic is now focussing its efforts on the production of the Delta Class spaceships. The new spaceships remain on track to enter commercial service in 2026, the company said.
Delta Class will&nbsp;<a href="https://www.benzinga.com/news/24/06/39247906/planes-just-cant-compete-elon-musk-boasts-rocket-booster-superiority-after-richard-bransons-virgin-g" target="_blank" rel="noreferrer noopener">replace the company's VSS Unity spaceplane</a>&nbsp;which had its last commercial flight in the second quarter. 
Announces At-The-Market Equity Program: Virgin Galactic on Wednesday also said that it entered into a sales agreement under which it may offer and sell shares of its common stock having an aggregate offering price of up to $300 million from time to time pursuant to an "at the market" program.
The proceeds from the program, it said, will be used to accelerate the development and production of its next-generation spaceflight fleet, including an additional carrier plane such as the company&#8217;s VMS Eve dual fuselage jet carrier aircraft and third and fourth Delta Class spaceships.
Price Action: Virgin Galactic shares closed up 3.5% on Wednesday at $7.12. The stock, however, is down by about 85% year-to-date, according to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="650" height="450" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07041713/newplot-15.jpeg" alt="" class="wp-image-634803" style="width:920px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07041713/newplot-15.jpeg 650w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07041713/newplot-15-300x208.jpeg 300w" sizes="(max-width: 650px) 100vw, 650px" /></figure>
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41767169/spacex-completes-400th-successful-falcon-launch-to-date-but-will-miss-target-of-144-launches-in-2024" target="_blank" rel="noreferrer noopener">SpaceX Completes 400th Successful Falcon Launch To Date, But Will Miss Target Of 144 Launches In 2024, Says Company Exec</a></li>
</ul>
Photo courtesy: Shutterstock

SPACE

SPCE

Richard Branson's Spaceflight Startup Virgin Galactic Sees Stock Surge After Narrowing Q3 Losses, Announces $300M Stock Sale

Needham analyst Joshua Reilly maintains Vertex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERX#NASDAQ">VERX</a>) with a Buy and raises the price target from $45 to $60.

VERX

Needham Maintains Buy on Vertex, Raises Price Target to $60

Truist Securities analyst Greg Miller maintains Booking Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKNG#NASDAQ">BKNG</a>) with a Hold and raises the price target from $4100 to $4700.

BKNG

Truist Securities Maintains Hold on Booking Holdings, Raises Price Target to $4700

Needham analyst James Ricchiuti maintains Kornit Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRNT#NASDAQ">KRNT</a>) with a Buy and raises the price target from $27 to $31.

KRNT

Needham Maintains Buy on Kornit Digital, Raises Price Target to $31

B of A Securities analyst Julien Dumoulin-Smith maintains TPI Composites (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPIC#NASDAQ">TPIC</a>) with a Buy and lowers the price target from $7 to $4.

TPIC

B of A Securities Maintains Buy on TPI Composites, Lowers Price Target to $4

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Beam Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) with a Buy and maintains $80 price target.

BEAM

HC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target

B of A Securities analyst Dimple Gosa maintains NEXTracker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXT#NASDAQ">NXT</a>) with a Buy and lowers the price target from $65 to $52.

B of A Securities Maintains Buy on NEXTracker, Lowers Price Target to $52

B of A Securities analyst Julien Dumoulin-Smith maintains Fluence Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLNC#NASDAQ">FLNC</a>) with a Buy and lowers the price target from $25 to $24.

FLNC

B of A Securities Maintains Buy on Fluence Energy, Lowers Price Target to $24

Needham analyst Mike Cikos maintains Cellebrite DI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLBT#NASDAQ">CLBT</a>) with a Buy and raises the price target from $17 to $21.

CLBT

Needham Maintains Buy on Cellebrite DI, Raises Price Target to $21

B of A Securities analyst Julien Dumoulin-Smith maintains Enphase Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>) with a Underperform and lowers the price target from $72 to $62.

ENPH

B of A Securities Maintains Underperform on Enphase Energy, Lowers Price Target to $62

Needham analyst Gil Blum reiterates Amicus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOLD#NASDAQ">FOLD</a>) with a Hold.

FOLD

Needham Reiterates Hold on Amicus Therapeutics

B of A Securities analyst Julien Dumoulin-Smith maintains Bloom Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>) with a Underperform and lowers the price target from $8 to $7.

B of A Securities Maintains Underperform on Bloom Energy, Lowers Price Target to $7

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Bionano Genomics (NASDAQ:<a href="https://investorplace.com/stock-quotes/bngo-stock-quote/">BNGO</a>) just reported results for the second quarter of 2024.<ul><li>Bionano Genomics reported earnings per share of -24 cents. This was above the analyst estimate for EPS of -42 cents.</li><li>The company reported revenue of $7.77 million.</li><li>This was 2.86% worse than the analyst estimate for revenue of $8.00 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/bngo-stock-earnings-bionano-genomics-for-q2-of-2024/">BNGO Stock Earnings: Bionano Genomics Beats EPS, Misses Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

BNGO Stock Earnings: Bionano Genomics Beats EPS, Misses Revenue for Q2 2024

Maxim Group analyst Jason McCarthy maintained a Hold rating on BioNano Genomics (BNGO – Research Report) yesterday. The company's shares closed tod...

Maxim Group Reaffirms Their Hold Rating on BioNano Genomics (BNGO)

Bionano Genomics, Inc. (BNGO) Canaccord Genuity 44th Annual Growth Conference (Transcript)

BTIG analyst Mark Massaro has reiterated their bullish stance on BNGO stock, giving a Buy rating on August 8. Mark Massaro has given his Buy rating...

Buy Rating Affirmed for BioNano Genomics Amidst Operational Progress and Strategic Financial Planning

BioNano Genomics ( ($BNGO) ) just unveiled an announcement. Bionano Genomics, Inc. is undergoing a significant reorganization to cut costs and opti...

BioNano Genomics Restructures for Cost Efficiency and Cash Flow Optimization

BioNano Genomics (BNGO – Research Report) received a Hold rating and price target from BTIG analyst Mark Massaro today. The company's shares closed...

BTIG downgrades BioNano Genomics (BNGO) to a Hold

BTIG downgrades Bionano to Neutral after fourth workforce reduction

Bionano Genomics cuts Q3 revenue view to $6.5M-$6.8M from $7.9M-$8.9M

Bionano Genomics (BNGO) announced the publication in Blood Cancer Journal by a group of researchers at the Korea College of Medicine in South Korea...

Bionano Genomics announces publication outlining utility of OGM

BioNano Genomics ( ($BNGO) ) has shared an update. Bionano Genomics announced a $3 million registered direct offering involving the sale of nearly ...

BioNano Genomics Announces $3M Direct Offering Initiative

BNGO

Press Releases

Bionano to Present at the Canaccord Genuity 44th Annual Growth Conference

Bionano Announces Presentation of Optical Genome Mapping Utility Across Cancer Research Applications at the Cancer Genomics Consortium (CGC) 2024 Annual Meeting

Comments

Bionano Genomics

Notizie

Ultime notizie per Bionano Genomics (NASDAQ:BNGO) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO